Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elena Mead

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Cancer Discovery|June 9, 2018
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaBianca D Santomasso, Jae H Park, Darin Salloum, et al.
Blood Cancer Journal|August 8, 2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M Lia Palomba, Martina Pennisi, et al.
Transplantation and Cellular Therapy|March 30, 2021
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, et al.
Blood Advances|February 22, 2020
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for managementMartina Pennisi, Tania Jain, Bianca D Santomasso, et al.
Blood Advances|August 12, 2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsDaniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Critical Care Medicine|July 14, 2021
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter StudyCristina Gutierrez, Anne Rain T Brown, Heather P May, et al.
Critical Care Medicine|December 30, 2025
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICUPrabalini Rajendram, R Scott Stephens, Anne Rain T Brown, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Nature Medicine|July 3, 2023
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim resultsJae H Park, Karthik Nath, Sean M Devlin, et al.
Blood Advances|July 3, 2020
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortalityKitsada Wudhikarn, Martina Pennisi, Marta Garcia-Recio, et al.
Cancer Discovery|June 9, 2018
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic LeukemiaBianca D Santomasso, Jae H Park, Darin Salloum, et al.
Blood Cancer Journal|August 8, 2020
Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphomaKitsada Wudhikarn, M Lia Palomba, Martina Pennisi, et al.
Transplantation and Cellular Therapy|March 30, 2021
The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell TherapyMarta Garcia-Recio, Kitsada Wudhikarn, Martina Pennisi, et al.
Blood Advances|February 22, 2020
Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for managementMartina Pennisi, Tania Jain, Bianca D Santomasso, et al.
Blood Advances|August 12, 2020
Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignanciesTania Jain, Andrea Knezevic, Martina Pennisi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 29, 2018
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsDaniel W Lee, Bianca D Santomasso, Frederick L Locke, et al.
Critical Care Medicine|July 14, 2021
Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter StudyCristina Gutierrez, Anne Rain T Brown, Heather P May, et al.
Critical Care Medicine|December 30, 2025
Six-Year Trends in ICU Admission, Management, and Outcomes of Chimeric Antigen Receptor T-Cell Patients in the ICUPrabalini Rajendram, R Scott Stephens, Anne Rain T Brown, et al.
Pageof 3